loading page

Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin for Atrial Fibrillation in Cancer Patients: A Systematic Review and Meta-analysis
  • +5
  • Bilal Hussain,
  • Mubashar Karamat,
  • Mohammad Hamza,
  • Ritu Yadav,
  • Yasar Sattar,
  • Ryan Berry,
  • Junaid Mir,
  • Brijesh D. Patel
Bilal Hussain
Brooklyn Hospital Center
Author Profile
Mubashar Karamat
Ascension Saint Francis
Author Profile
Mohammad Hamza
Albany Medical Center
Author Profile
Ritu Yadav
Midwestern University
Author Profile
Yasar Sattar
West Virginia University
Author Profile
Ryan Berry
Authority Health
Author Profile
Junaid Mir
University of Missouri Department of Medicine
Author Profile
Brijesh D. Patel
West Virginia University

Corresponding Author:[email protected]

Author Profile

Abstract

Background Patients with cancer are at increased risk of atrial fibrillation (AF) while cancer is also associated with increased risk of thromboembolism as well as bleeding. Direct oral anticoagulants (DOACs) have emerged as an alternative to warfarin for AF to reduce thromboembolic events, however, the studies on these anticoagulation strategies in cancer patients are limited. Objective We aimed to conduct a systematic review and meta-analysis to compare the efficacy and safety of DOACs vs warfarin in cancer patients. Methods 13 studies were included in the meta-analysis comparing DOAC treatment to warfarin for AF in cancer patients. Outcomes studied were all-cause mortality, cardiovascular death, acute myocardial infarction (AMI), bleeding and thromboembolic events. Mantel-Haenszel method was used to calculate pooled log odds-ratio (OR) for binary outcomes and Hedges’ g using inverse-variance method for continuous outcomes. We used random effects model with 95% confidence interval (CI) for statistical significance. Results DOACs as compared to warfarin in cancer patients with AF were associated with decreased odds of all-cause mortality (OR 0.67, 95% CI 0.48-0.94, I 2=96%, p=0.019), cardiovascular deaths (OR 0.62, 95% CI 0.49-0.79, I 2= 0%, p<0.001), AMI (OR 0.66, 95% CI 0.49-0.89, I 2= 0%, p<0.01), combined ischemic stroke and systemic embolic events.